MEI Pharma Inc. (MEIP)
MEI Pharma Statistics
Share Statistics
MEI Pharma has 6.66M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 6.66M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 2.19% |
| Shares Floating | 6.58M |
| Failed to Deliver (FTD) Shares | 335 |
| FTD / Avg. Volume | 3.38% |
Short Selling Information
The latest short interest is 2.63K, so 0.04% of the outstanding shares have been sold short.
| Short Interest | 2.63K |
| Short % of Shares Out | 0.04% |
| Short % of Float | 0.05% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 1.07 and the forward PE ratio is -0.53. MEI Pharma's PEG ratio is -0.01.
| PE Ratio | 1.07 |
| Forward PE | -0.53 |
| PS Ratio | 0.29 |
| Forward PS | 0.5 |
| PB Ratio | 0.58 |
| P/FCF Ratio | -0.38 |
| PEG Ratio | -0.01 |
Enterprise Valuation
MEI Pharma has an Enterprise Value (EV) of 15.28M.
| EV / Sales | 0.23 |
| EV / EBITDA | 0.58 |
| EV / EBIT | -0.3 |
| EV / FCF | -0.3 |
Financial Position
The company has a current ratio of 4.88, with a Debt / Equity ratio of 0.
| Current Ratio | 4.88 |
| Quick Ratio | 4.88 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 53.84% and Return on Invested Capital is 44.04%.
| Return on Equity | 53.84% |
| Return on Assets | 42.97% |
| Return on Invested Capital | 44.04% |
| Revenue Per Employee | $2.33M |
| Profits Per Employee | $634.93K |
| Employee Count | 28 |
| Asset Turnover | 1.58 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -39.38% in the last 52 weeks. The beta is 0.61, so MEI Pharma's price volatility has been higher than the market average.
| Beta | 0.61 |
| 52-Week Price Change | -39.38% |
| 50-Day Moving Average | 2.36 |
| 200-Day Moving Average | 2.78 |
| Relative Strength Index (RSI) | 36.86 |
| Average Volume (20 Days) | 9.91K |
Income Statement
In the last 12 months, MEI Pharma had revenue of 65.3M and earned 17.78M in profits. Earnings per share was 2.67.
| Revenue | 65.3M |
| Gross Profit | 64.91M |
| Operating Income | 14.54M |
| Net Income | 17.78M |
| EBITDA | 26.38M |
| EBIT | 25.44M |
| Earnings Per Share (EPS) | 2.67 |
Balance Sheet
The company has 3.71M in cash and 0 in debt, giving a net cash position of 3.71M.
| Cash & Cash Equivalents | 3.71M |
| Total Debt | 0 |
| Net Cash | 3.71M |
| Retained Earnings | -388.22M |
| Total Assets | 24.39M |
| Working Capital | 22.1M |
Cash Flow
In the last 12 months, operating cash flow was -50.47M and capital expenditures -7K, giving a free cash flow of -50.48M.
| Operating Cash Flow | -50.47M |
| Capital Expenditures | -7K |
| Free Cash Flow | -50.48M |
| FCF Per Share | -7.58 |
Margins
Gross margin is 99.41%, with operating and profit margins of 22.27% and 27.23%.
| Gross Margin | 99.41% |
| Operating Margin | 22.27% |
| Pretax Margin | 27.23% |
| Profit Margin | 27.23% |
| EBITDA Margin | 40.4% |
| EBIT Margin | 22.27% |
| FCF Margin | -77.31% |
Dividends & Yields
MEIP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 93.62% |
| FCF Yield | -265.83% |
Analyst Forecast
The average price target for MEIP is $7, which is 255.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $7 |
| Price Target Difference | 255.3% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Apr 17, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 17, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -22.52 |
| Piotroski F-Score | 2 |